Analyst firms · H.C. Wainwright · ARCT

H.C. Wainwright ARCT price target and rating history

Arcturus Therapeutics Holdings Inc. (ARCT) · Health Care

H.C. Wainwright rates Arcturus Therapeutics Holdings Inc. (ARCT) Neutral with a $12 price target, as of its latest action on Oct 24, 2025. It has published 3 rating actions on ARCT since May 2023, including 1 upgrade and 1 downgrade. Across 3 firms with a ARCT price target in the last 12 months, the median target is $20.

Current rating
Neutral
Price target
$12
Median target, all firms
$20
Actions on ARCT
3

H.C. Wainwright price target on ARCT

$60$36$12202420252026
H.C. Wainwright price target on ARCT, each point a stated target, May 2023 to October 2025.

Every H.C. Wainwright rating on ARCT

How other firms rate ARCT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
CitigroupBuy$20Sep 24, 2026
B. Riley SecuritiesBuy$22Mar 18, 2026
Roth CapitalBuy$20Jan 23, 2026

Questions about H.C. Wainwright and ARCT

What is H.C. Wainwright's price target for ARCT?
H.C. Wainwright's latest stated price target for Arcturus Therapeutics Holdings Inc. (ARCT) is $12, from its action on Oct 24, 2025.
What is H.C. Wainwright's rating on ARCT?
H.C. Wainwright rates ARCT Neutral, a neutral rating, as of Oct 24, 2025.
When did H.C. Wainwright last change its view on ARCT?
On Oct 24, 2025, H.C. Wainwright downgrades to Neutral from Buy, price target $12.
How does H.C. Wainwright's ARCT target compare with other analysts?
Across 3 firms with a ARCT price target in the last 12 months, the median target is $20.

More ARCT rating histories

All H.C. Wainwright ratingsARCT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.